id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-309026-l2rh9bie	Sweiss, Nadera J.	When the game changes: Guidance to adjust sarcoidosis management during the COVID-19 pandemic	2020-04-29		.txt	text/plain	1537	75	44	Over the past few months, the novel coronavirus disease (COVID-19) pandemic has posed many challenges for practicing phyicians.Sarcoidosis patients may have an increased risk of a poor outcome and death from COVID-19 infection for several reasons. 4 Little is known about the impact of sarcoidosis treatments on susceptibility to and disease expression of COVID-19 infection; however, because of the lethality of COVID-19 infection, there is concern that the risk-benefit ratio of effective immunosuppressive therapies for sarcoidosis may be altered in the current climate. In this document, we aim to provide clinicians with practical guidance on how to adjust immunosuppressive therapy for the treatment of sarcoidosis during the COVID-19 pandemic. Patients who receive immunosuppressive biologic agents may be at increased risk of COVID-19 infection. If very high-doses of GC (e.g., >40-60 mg of prednisone per day) are necessary, the addition of a DMASD may be prudent to enable a reduction of GC requirements, since GC therapy is associated with a high risk of infection in sarcoidosis patients.	./cache/cord-309026-l2rh9bie.txt	./txt/cord-309026-l2rh9bie.txt